Lupin launches Meloxicam Capsules
They are indicated for the management of osteoarthritis pain
Lupin announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (US FDA).
Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, and indicated for the management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $11 million in the US (IQVIA MAT October 2020).